Literature DB >> 4366052

Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man.

M S Brown, J L Goldstein.   

Abstract

Studies in ctltured fibroblasts indicate that the primary genetic abnormality in familial hypercholesterolemia involves a deficiency in a cell surface receptor for low density lipoproteins (LDL). In normal cells, binding of LDL to this receptor regulates cholesterol metabolism by suppressing cholesterol synthesis and increasing LDL degradation. In cells from heterozygotes, a 60 percent reduction in LDL receptors leads to a concentration-dependent defect in regulation, so that attainment of equal rates of cholesterol synthesis and LDL degradation in normal and heterozygous cells requires a two- to threefold higher concentration of LDL in the heterozygote. The identification of this genetic regulatory defect in fibroblasts of heterozygotes makes available an in vitro system for studying the effects of a dominant mutation on gene expression in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4366052     DOI: 10.1126/science.185.4145.61

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  64 in total

1.  Detection of clinically relevant exonic copy-number changes by array CGH.

Authors:  Philip M Boone; Carlos A Bacino; Chad A Shaw; Patricia A Eng; Patricia M Hixson; Amber N Pursley; Sung-Hae L Kang; Yaping Yang; Joanna Wiszniewska; Beata A Nowakowska; Daniela del Gaudio; Zhilian Xia; Gayle Simpson-Patel; LaDonna L Immken; James B Gibson; Anne C-H Tsai; Jennifer A Bowers; Tyler E Reimschisel; Christian P Schaaf; Lorraine Potocki; Fernando Scaglia; Tomasz Gambin; Maciej Sykulski; Magdalena Bartnik; Katarzyna Derwinska; Barbara Wisniowiecka-Kowalnik; Seema R Lalani; Frank J Probst; Weimin Bi; Arthur L Beaudet; Ankita Patel; James R Lupski; Sau Wai Cheung; Pawel Stankiewicz
Journal:  Hum Mutat       Date:  2010-11-02       Impact factor: 4.878

2.  In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.

Authors:  P W Stacpoole; D M Bridge; I M Alvarez; R B Goldberg; H J Harwood
Journal:  J Clin Invest       Date:  1987-11       Impact factor: 14.808

3.  Lipoprotein receptors and genetic control of cholesterol metabolism in cultured human cells.

Authors:  M S Brown; J L Goldstein
Journal:  Naturwissenschaften       Date:  1975-08

4.  Role of the low density lipoprotein receptor in regulating the content of free and esterified cholesterol in human fibroblasts.

Authors:  M S Brown; J R Faust; J L Goldstein
Journal:  J Clin Invest       Date:  1975-04       Impact factor: 14.808

Review 5.  Genetics and personalized medicine--a role in statin therapy?

Authors:  Jaideep Patel; Thura Abd; Roger S Blumenthal; Khurram Nasir; H Robert Superko
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

6.  Receptor-dependent hydrolysis of cholesteryl esters contained in plasma low density lipoprotein.

Authors:  M S Brown; S E Dana; J L Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

7.  Four DNA polymorphisms in the LDL receptor gene: their genetic relationship and use in the study of variation at the LDL receptor locus.

Authors:  R Taylor; M Jeenah; M Seed; S Humphries
Journal:  J Med Genet       Date:  1988-10       Impact factor: 6.318

8.  Calcium as a crucial cofactor for low density lipoprotein receptor folding in the endoplasmic reticulum.

Authors:  Florentina Pena; Annemieke Jansens; Guus van Zadelhoff; Ineke Braakman
Journal:  J Biol Chem       Date:  2010-01-20       Impact factor: 5.157

9.  Common and rare gene variants affecting plasma LDL cholesterol.

Authors:  John R Burnett; Amanda J Hooper
Journal:  Clin Biochem Rev       Date:  2008-02

Review 10.  Genomics in cardiovascular disease.

Authors:  Robert Roberts; A J Marian; Sonny Dandona; Alexandre F R Stewart
Journal:  J Am Coll Cardiol       Date:  2013-03-21       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.